Search
Merus NV
MRUSAdd to Watchlist
90.000USD
0.0000.00%
Market hours （ET）Quotes delayed by 15 min
6.83BMarket Cap
LossP/E TTM
More Details of Merus NV Company
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Merus NV Info
Ticker SymbolMRUS
Company nameMerus NV
IPO dateMay 19, 2016
CEOLundberg (Sven Ante)
Number of employees260
Security typeOrdinary Share
Fiscal year-endMay 19
AddressYalelaan 62
CityUTRECHT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code3584 CM
Phone310302538800
Websitehttps://merus.nl/
Ticker SymbolMRUS
IPO dateMay 19, 2016
CEOLundberg (Sven Ante)
Company Executives of Merus NV
Name
Name/Position
Position
Shareholding
Change
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
168.44K
-17.99%
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Gregory D. (Greg) Perry
Mr. Gregory D. (Greg) Perry
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Leonard (Len) Kanavy
Mr. Leonard (Len) Kanavy
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paolo Pucci
Mr. Paolo Pucci
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
168.44K
-17.99%
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Gregory D. (Greg) Perry
Mr. Gregory D. (Greg) Perry
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Leonard (Len) Kanavy
Mr. Leonard (Len) Kanavy
Non-Executive Independent Director
Non-Executive Independent Director
--
--
FAQs
Who are the top five shareholders of Merus NV?
The top five shareholders of Merus NV are: Dr. Sven Ante (Bill) Lundberg, M.D.
How many institutions hold shares of Merus NV (MRUS)?
As of 2025Q4, 498 institutions hold shares of Merus NV, with a combined market value of approximately 69.89M, accounting for 92.15% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -15184959.00.
